Sign in
NVCR Stock Price, Chart, Stats & News
Novocure Ltd
Save
Novocure Ltd (NVCR) does not currently pay a dividend.
1.86B
Market cap
–
Current P/E
909.09x
Forward P/E
NVCR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 74.54% |
Operating margin | -23.47% |
Pretax margin | -20.79% |
Net margin | -20.79% |
Effective tax rate | 0.02% |
ROA | -16.94% |
ROE | -39.11% |
D/E | 0.85x |
Interest coverage ratio | – |
NVCR valuation
P/E | – |
P/S | 1.90x |
P/B | 3.59x |
P/CF | -24.94x |
P/FCF | -16.49x |
P/OCF | -24.94x |
PEG | -0.37x |
EV multiple | -8.09x |
About
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Similar securities
Based on sector and market capitalization
Report issue